R
Richard B. Kim
Researcher at University of Western Ontario
Publications - 380
Citations - 33088
Richard B. Kim is an academic researcher from University of Western Ontario. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 89, co-authored 328 publications receiving 30436 citations. Previous affiliations of Richard B. Kim include London Health Sciences Centre & St. Jude Children's Research Hospital.
Papers
More filters
Journal ArticleDOI
Identification and functional characterization of a new CYP2C9 variant (CYP2C9*5) expressed among African Americans.
Leslie J. Dickmann,Allan E. Rettie,M.Byron Kneller,Richard B. Kim,Alastair J. J. Wood,C. Michael Stein,Grant R. Wilkinson,Ute I. Schwarz +7 more
TL;DR: DNA from 140 European Americans and 120 African Americans was examined by single-strand conformational polymorphism and restriction fragment length polymorphism analyses, resulting in the identification of a new CYP2C9 variant, CYP 2C9*5.
Journal Article
MDR1 Gene Polymorphisms Affect Therapy Outcome in Acute Myeloid Leukemia Patients
Thomas Illmer,Ulrich Schuler,Christian Thiede,Ute I. Schwarz,Richard B. Kim,Sebastian Gotthard,Daniel Freund,Ulrike Schäkel,Gerhard Ehninger,Markus Schaich +9 more
TL;DR: Analysis of acute myeloid leukemia patients investigated for somatic genotypes of the three most frequent single nucleotide polymorphisms (SNPs) in exons 12, 21, and 26 indicates that allelic variants of the MDR1 gene may influence therapy outcome by additional mechanisms, different from P-gp expression on acute myELoid leukemia blasts.
Journal ArticleDOI
Pharmacogenetics of Plasma Efavirenz Exposure after Treatment Discontinuation: An Adult AIDS Clinical Trials Group Study
Heather J. Ribaudo,David W. Haas,Camlin Tierney,Richard B. Kim,Grant R. Wilkinson,Roy M. Gulick,David B. Clifford,Catia Marzolini,Courtney V. Fletcher,Karen T. Tashima,Daniel R. Kuritzkes,Edward P. Acosta +11 more
TL;DR: The CYP2B6 position 516 TT genotype or a prolonged measured elimination half-life may predict increased risk of developing drug resistance among patients who discontinue efavirenz-containing regimens.
Journal ArticleDOI
Interaction of morphine, fentanyl, sufentanil, alfentanil, and loperamide with the efflux drug transporter P-glycoprotein.
TL;DR: Opioids have a wide spectrum of P-glycoprotein activity, acting as both substrates and inhibitors, which might contribute to their varying central nervous system–related effects.
Journal ArticleDOI
Transporters and Renal Drug Elimination
Wooin Lee,Richard B. Kim +1 more
TL;DR: Recent progress in terms of molecular and functional characterization of renal transporters and their clinical relevance to drug therapy is summarized.